Josh Disbrow

Josh Disbrow has emerged as a distinguished luminary within the pharmaceutical sector, boasting an extensive quarter-century of experience across pharmaceuticals, diagnostics, and medical devices. His journey is symbolic of success, highlighted by the triumphant inception of Aytu BioPharma, impressive growth trajectory, and substantial contributions to renowned pharmaceutical entities. Beyond his professional achievements, Josh’s persona is enriched by profound familial ties, a musical inclination, and a genuine commitment to philanthropy. Josh holds the reins as the Chief Executive Officer and Board Director of Aytu BioPharma, a venture he co-founded in 2015. Under his visionary leadership, Aytu BioPharma attained the prestigious NASDAQ listing in 2017, a feat made more remarkable by surpassing $100 million in annual revenues within a mere seven years. His strategic insight is further evident in steering the company through four pivotal acquisitions within less than four years, cementing its position within the industry. Beyond Aytu BioPharma, Josh’s influence extends to his role as a Director at Zynex, Inc., a publicly-listed medical device firm specializing in electrotherapy and pain management.

Josh’s professional journey embarked with him as a sales representative at Glaxo Wellcome, a prelude to his ascension into pivotal commercial and leadership roles at distinguished establishments such as Cyberonics, LipoScience, Arbor Pharmaceuticals, and Ampio Pharmaceuticals. At Arbor, he orchestrated a transformative transition, propelling the company from pre-commercialization to an impressive revenue of over $250 million in less than five years. A robust academic foundation complements Josh’s profound industry insights. Armed with a Bachelor of Science in Management, he graduated with honors from North Carolina State University. This bedrock of knowledge was further enriched by his acquisition of a Master of Business Administration from Wake Forest University School of Business.

Learn more